• Bull.

    HEDGEYE'S DEAL OF THE MONTH

    TRY OUR DAILY MACRO PLAYBOOK

    FREE FOR 30 DAYS!

In today’s clip from The Call @ Hedgeye, Hedgeye Health Policy analyst Emily Evans questions the soundness of Pfizer's new RSV vaccine targeted at pregnant women. Evans argues that the FDA's approval of the vaccine is "incredibly silly" because RSV is not a major threat to public health, even though it can be deadly. She explains that RSV is a “risk profile kind of infection that does not kill a lot of people.”

Evans adds, "My other theory that I want to explore is that the FDA, because they are supported, their budget comes from the industry, and it comes from applications for drug approvals. If they don't approve drugs, they don't have a budget… and this could be a problem."

Watch the full clip above.

Is New Pfizer RSV Vaccine an FDA Money Grab? - Call Banner